Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new National Institute for Health and Care Research (NIHR) BioResource aimed at investigating inflammatory bowel disease (IBD) in children has opened, with the NIHR Oxford BRC playing a key role.

The new Paediatric Inflammatory Bowel Disease (PIBD) BioResource will drive research into Crohn’s Disease & ulcerative colitis in children. It aims to recruit paediatric IBD patients to investigate genetic, immunological mechanisms and environmental factors. The PIBD BioResource is led by the University of Oxford’s Professor Holm Uhlig, a senior researcher in the Oxford BRC’s Gastroenterology and Mucosal Immunity Theme, and is run in collaboration with Cambridge University Hospitals (CUH), the NIHR BioResource and paediatric IBD centres throughout the UK.

The NIHR BioResource is a national panel of volunteers who have consented to participate in health research. Children recruited to the PIBD Bioresource participate by providing blood, biopsy and stool samples as well as health and lifestyle data. The PIBD aims to establish a resource of over 5,000 patients with paediatric onset IBD in the BioResource. 

Professor Holm UhligProfessor Uhlig (pictured left) said: “Inflammatory bowel diseases in children are increasing in numbers in the UK and worldwide. The PIBD BioResource research network provides the scientific research community with a resource of data and samples to study mechanisms of paediatric onset IBD required to develop better diagnostics and medicines.

“The first paediatric IBD patient was recruited to the PIBD BioResource in April 2022 in Oxford. This patient had developed IBD at a very early age and required several medicines to control the disease. There is substantial unmet need to understand the genetic factors that cause IBD and help to identify novel precision therapies. Our collaborative project will support both UK and international research towards more personalised medicine in PIBD.”

Read the full story on the NIHR Oxford Biomedical Centre website. 

Similar stories

Long COVID: vaccination could reduce symptoms, new research suggests

While evidence suggests that people who are vaccinated before they get COVID are less likely to develop long COVID than unvaccinated people, the effectiveness of vaccination on existing long COVID has been less clear.

Com-COV vaccine study to research third dose booster options for 12-to-15-year-olds

Researchers running the University of Oxford-led Com-COV programme have launched a further study of COVID-19 vaccination schedules in young people aged 12 to 15 – with a focus on assessing different options for a third dose booster vaccination.

Population-scale study highlights ongoing risk of COVID-19 in some cancer patients despite vaccination

COVID-19 vaccination is effective in most cancer patients, but the level of protection against COVID-19 infection, hospitalisation and death offered by the vaccine is less than in the general population and vaccine effectiveness wanes more quickly.

New reporting guidelines developed to improve AI in healthcare settings

New reporting guidelines, jointly published in Nature Medicine and the BMJ by Oxford researchers, will ensure that early studies on using Artificial Intelligence (AI) to treat real patients will give researchers the information needed to develop AI systems safely and effectively.

Major boost for Oxford’s mission to counter future pandemic threats

The Moh Family Foundation has given a substantial gift to support the work of Oxford University’s Pandemic Sciences Institute, greatly strengthening its ability to identify and counter future pandemic threats and ensure equitable access to treatments and vaccines around the world.